Physician profile
Yayan Chen
NPI 1003859398
$2,018.43
in general payments reported to CMS, 2019-2025
26 companies · $610 in 2025
The $610 reported for 2025 was more than what 87% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $228 · 2021: $21.61 · 2022: $54.94 · 2023: $190 · 2024: $312 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,112.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $366.05 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| Astrazeneca Pharmaceuticals Lp | $351.86 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $270.17 | 2019-2023 | Opdivo |
| Eisai INC. | $168.07 | 2019-2025 | |
| Seagen INC. | $102.60 | 2019-2023 | Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $95.20 | 2019-2022 | |
| Karyopharm Therapeutics INC. | $77.54 | 2025 | Xpovio |
| Incyte Corporation | $69.33 | 2019-2023 | Jakafi |
| Geron Corporation | $61.12 | 2024-2025 | Rytelo |
| Pharmacyclics LLC, An Abbvie Company | $49.96 | 2019-2022 | |
| Exelixis INC. | $34.98 | 2023 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $33.64 | 2024 | Libtayo |
| Abbvie INC. | $33.44 | 2025 | |
| Blue Earth Diagnostics | $32.96 | 2025 | Posluma |
| Sobi, INC | $32.96 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $32.66 | 2025 | Rybrevant |
| Beigene USA, INC. | $27.98 | 2024 | Brukinsa |
| Servier Pharmaceuticals LLC | $24.98 | 2025 | |
| Roche Diagnostics Corporation | $24.08 | 2020 | |
| Celgene Corporation | $22.82 | 2019 | |
| Ortho-Clinical Diagnostics, INC. | $21.61 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.00 | 2019 | |
| Eyevance Pharmaceuticals LLC | $17.40 | 2023 | Flarex |
| Lilly USA, LLC | $17.08 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.55 | 2019 | |
| Pfizer INC. | $14.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yayan Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.